Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The synaptic vesicle release machinery comprises a network of interacting proteins that regulate all steps of neurotransmitter exocytosis at presynaptic nerve terminals. The central component is the SNARE complex, consisting of Syntaxin-1, Synaptobrevin (VAMP2), and SNAP-25, which drives membrane fusion between synaptic vesicles and the presynaptic membrane. This process is tightly regulated by proteins such as Synaptotagmin-1 (the calcium sensor for fast release), Complexin (fusion clamp/activator), Munc13 (priming factor), Munc18 (SNARE chaperone), and Synaptophysin (vesicle trafficking regulator)[1][3][4][5][6][8]. Disruption in the function or balance of these proteins leads to severe defects in synaptic transmission and is implicated in multiple neurological and psychiatric disorders[5]. The machinery is a target for bacterial neurotoxins but not for approved therapeutics.
Proteolytic cleavage of SNARE proteins (e.g., botulinum and tetanus toxins inhibit vesicular fusion by cleaving SNAREs) Inhibition of SNARE complex assembly and exocytosis
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Synaptic vesicle release machinery.